{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T22:37:54Z","timestamp":1792449474046,"version":"4.5.0"},"reference-count":28,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2010,10,13]],"date-time":"2010-10-13T00:00:00Z","timestamp":1286928000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmacoepidemiology and Drug"],"published-print":{"date-parts":[[2010,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Purpose<\/jats:title><jats:p>To evaluate and quantify in diabetic patients treated with benfluorex in France, a fenfluramine\u2010derivated product, a possible increase in risk of valvular heart disease, previously suggested by several published case reports.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a French comparative cohort study using data from two large national linked databases, health insurance system (SNIIRAM) and hospitalization (PMSI). Patients aged 40\u201369 years with reimbursement for oral antidiabetic and\/or insulin in 2006 were eligible. Exposed patients were defined as patients with at least one benfluorex reimbursement in 2006. Selected admission diagnoses of interest in 2007 and 2008 PMSI databases were valvular insufficiency for any cause, mitral insufficiency, aortic insufficiency, and valvular replacement surgery with cardiopulmonary bypass. Relative risks (RR) were adjusted on gender, age, and history of chronic cardiovascular disease.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>A total of 1\u2009048\u2009173 diabetic patients were included, with 43\u2009044 (4.1%) exposed to benfluorex. The risk of hospitalization in 2007 and 2008 for any cardiac valvular insufficiency was higher in the benfluorex group: crude RR\u2009=\u20092.9 [95% confidence interval 2.2\u20133.7] and adjusted RR\u2009=\u20093.1 [2.4\u20134.0], with a lower risk for patients with lower cumulative dose of benfluorex. Adjusted RR for mitral insufficiency and aortic insufficiency admissions were 2.5 [1.9\u20133.7] and 4.4 [3.0\u20136.6], respectively. Adjusted RR for valvular replacement surgery was 3.9 [2.6\u20136.1].<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Benfluorex in diabetic patients was significantly associated with hospitalization for valvular heart disease in the 2 years following benfluorex exposure. Linkage between SNIIRAM and PMSI databases is in France a valuable tool to quantify the risk of serious adverse drug reactions. Copyright \u00a9 2010 John Wiley &amp; Sons, Ltd.<\/jats:p><\/jats:sec>","DOI":"10.1002\/pds.2044","type":"journal-article","created":{"date-parts":[[2010,10,14]],"date-time":"2010-10-14T13:48:53Z","timestamp":1287064133000},"page":"1256-1262","source":"Crossref","is-referenced-by-count":143,"title":["Benfluorex and valvular heart disease: a cohort study of a million people with diabetes mellitus"],"prefix":"10.1002","volume":"19","author":[{"given":"Alain","family":"Weill","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Pa\u00efta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Tuppin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Paul","family":"Fagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anke","family":"Neumann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dominique","family":"Simon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Ricordeau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean\u2010Louis","family":"Montastruc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hubert","family":"Allemand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,10,13]]},"reference":[{"key":"e_1_2_8_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199608293350901"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199708283370901"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809103391102"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199809103391101"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1157\/13043231"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1472-8206.2006.00441.x"},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00086308"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1912"},{"key":"e_1_2_8_10_2","unstructured":"Website of Technical Hospitalization Information Agency (ATIH)http:\/\/www.atih.sante.fr\/en\/index.php?id=00000000."},{"key":"e_1_2_8_11_2","unstructured":"Pa\u00eftaM WeillA. Patients with long term disease on 31 December 2008.http:\/\/www.ameli.fr\/fileadmin\/user_upload\/documents\/27_\u2010_ALD_2008.pdf(accessed 28 December 2009) French."},{"key":"e_1_2_8_12_2","first-page":"409","article-title":"Treated diabetes in France in 2007: a prevalence rate close to 4% and increasing geographic disparities","volume":"43","author":"Kusnik\u2010Joinville O","year":"2008","journal-title":"Bull Epidemiol Hebd"},{"key":"e_1_2_8_13_2","first-page":"450","article-title":"Characteristics, vascular risk and complications in people with diabetes, in metropolitan France: major improvements between ENTRE 2001 and ENTRED 2007 studies","volume":"42","author":"Fagot\u2010Campagna A","year":"2009","journal-title":"Bull Epidemiol Hebd"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejogrb.2009.08.011"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-008-9282-y"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1177\/1076029608319441"},{"key":"e_1_2_8_17_2","first-page":"221","article-title":"Dyslipidemia: how well were practice guidelines followed before initiating treatment with lipid\u2010lowering agents in 2002 in France","volume":"34","author":"Saba G","year":"2003","journal-title":"Rev Med Ass Maladie"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1717"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabet.2007.11.005"},{"key":"e_1_2_8_20_2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0026-895X(24)26444-0","article-title":"Possible role of valvular serotonin 5\u2010HT(2B) receptors in the cardiopathy associated with fenfluramine","volume":"57","author":"Fitzgerald LW","year":"2000","journal-title":"Mol Pharmacol"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.102.23.2836"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp068265"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(09)60252-X"},{"key":"e_1_2_8_24_2","unstructured":"National Pharmacovigilance Committee: Minutes of Tuesday 29 September 2009 meeting.http:\/\/www.afssaps.fr\/var\/afssaps_site\/storage\/original\/application\/d3586501cd537d588059288f37135194.pdf(accessed 5 November 2009) French."},{"key":"e_1_2_8_25_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0010128"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1093\/ejechocard\/jeq027"},{"key":"e_1_2_8_27_2","first-page":"E1","article-title":"Changes by age in breast cancer incidence, mammography screening and hormone therapy use in France from 2000 to 2006","volume":"96","author":"S\u00e9radour B","year":"2009","journal-title":"Bull Cancer"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.1002\/pds.1836"},{"key":"e_1_2_8_29_2","unstructured":"Press release European Medicines Agency 18 December 2009 EMA\/CHMP\/815033\/2009 Press Office http:\/\/www.ema.europa.eu\/pdfs\/human\/referral\/benfluorex\/Benfluorex_81503309en.pdf(accessed 28 December 2009)."}],"container-title":["Pharmacoepidemiology and Drug Safety"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fpds.2044","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pds.2044","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,26]],"date-time":"2025-02-26T19:09:15Z","timestamp":1740596955000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pds.2044"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10,13]]},"references-count":28,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2010,12]]}},"alternative-id":["10.1002\/pds.2044"],"URL":"https:\/\/doi.org\/10.1002\/pds.2044","archive":["Portico"],"relation":{},"ISSN":["1053-8569","1099-1557"],"issn-type":[{"value":"1053-8569","type":"print"},{"value":"1099-1557","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,10,13]]}}}